Table 3 Cardioversion Strategies by Country as Reported in the Site Questionnaires
Total | AUS | BR | FR | DEU | ITL | NL | POL | ESP | SWE | UK | |
|---|---|---|---|---|---|---|---|---|---|---|---|
% (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | % (n/N) | |
Frequency “wait-and-see” approach | |||||||||||
never | 17.9 (31/173) | 12.5 (1/8) | 20.0 (2/10) | 12.0 (3/25) | 4.6 (1/22) | 0 | 0 | 20.0 (3/15) | 34.7 (17/49) | 0 | 28.6 (4/14) |
sometimes | 69.4 (120/173) | 75.0 (6/8) | 50.0 (5/10) | 60.0 (15/25) | 90.9 (20/22) | 80.0 (8/10) | 100 (6/6) | 66.7 (10/15) | 59.2 (29/49) | 92.9 (13/14) | 57.1 (8/14) |
frequent | 12.7 (22/173) | 12.5 (1/8) | 30.0 (3/10) | 28.0 (7/25) | 4.6 (1/22) | 20.0 (2/10) | 0 | 13.3 (2/15) | 6.1 (3/49) | 7.1 (1/14) | 14.3 (2/14) |
Frequency PCV | |||||||||||
never | 0.6 (1/173) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.1 (1/14) | 0 |
sometimes | 37.6 (65/173) | 50.0 (4/8) | 20.0 (2/10) | 32.0 (8/25) | 68.2 (15/22) | 40.0 (4/10) | 50.0 (3/6) | 20.0 (3/15) | 14.3 (7/49) | 85.7 (12/14) | 50.0 (7/14) |
frequent | 61.8 (107/173) | 50.0 (4/8) | 80.0 (8/10) | 68.0 (17/25) | 31.8 (7/22) | 60.0 (6/10) | 50.0 (3/6) | 80.0 (12/15) | 85.7 (42/49) | 7.1 (1/14) | 50.0 (7/14) |
Frequency ECV | |||||||||||
never | 0.6 (1/172) | 0 | 0 | 0 | 0 | 10.0 (1/10) | 0 | 0 | 0 | 0 | 0 |
sometimes | 32.6 (56/172) | 25.0 (2/8) | 30.0 (3/10) | 16.7 (4/24) | 0 | 70.0 (7/10) | 0 | 6.7 (1/15) | 67.4 (33/49) | 14.3 (2/14) | 28.6 (4/14) |
frequent | 66.9 (115/172) | 75.0 (6/8) | 70.0 (7/10) | 83.3 (20/24) | 100 (22/22) | 20.0 (2/10) | 100 (6/6) | 93.3 (14/15) | 32.6 (16/49) | 85.7 (12/14) | 71.4 (10/14) |
Preferred drugs for PCV* | |||||||||||
Amiodarone | 85.7 (150/175) | 100 (8/8) | 100 (10/10) | 81.5 (22/27) | 90.9 (20/22) | 60.0 (6/10) | 83.3 (5/6) | 93.3 (14/15) | 85.7 (42/49) | 64.3 (9/14) | 100 (14/14) |
Beta-blocker | 23.4 (41/175) | 12.5 (1/8) | 40.0 (4/10) | 0 | 40.9 (9/22) | 10.0 (1/10) | 16.7 (1/6) | 53.3 (8/15) | 12.2 (6/49) | 28.6 (4/14) | 50.0 (7/14) |
Dronedarone | 8.6 (15/175) | 0 | 0 | 0 | 45.5 (10/22) | 0 | 0 | 0 | 0 | 21.4 (3/14) | 14.3 (2/14) |
Flecainide | 60.6 (106/175) | 75.0 (6/8) | 0 | 33.3 (9/27) | 81.8 (18/22) | 60.0 (6/10) | 100 (6/6) | 0 | 91.8 (45/49) | 35.7 (5/14) | 78.6 (11/14) |
Propafenone | 26.9 (47/175) | 0 | 70.0 (7/10) | 3.7 (1/27) | 27.3 (6/22) | 80.0 (8/10) | 0 | 80.0 (12/15) | 20.4 (10/49) | 7.1 (1/14) | 14.3 (2/14) |
Sotalol | 12.0 (21/175) | 75.0 (6/8) | 20.0 (2/10) | 0 | 0 | 10.0 (1/10) | 33.3 (2/6) | 26.7 (4/15) | 2.0 (1/49) | 7.1 (1/14) | 28.6 (4/14) |
Verapamil | 6.3 (11/175) | 12.5 (1/8) | 10.0 (1/10) | 0 | 0 | 10.0 (1/10) | 0 | 13.3 (2/15) | 8.2 (4/49) | 0 | 14.3 (2/14) |
Other† | 5.1 (9/175) | 0 | 0 | 0 | 0 | 10.0 (1/10) | 33.3 (2/6) | 0 | 6.1 (3/49) | 14.3 (2/14) | 7.1 (1/14) |
Preferred type of ECV | |||||||||||
Mono | 5.8 (10/173) | 0 | 10.0 (1/10) | 12.0 (3/25) | 4.6 (1/22) | 10.0 (1/10) | 0 | 0 | 6.1 (3/49) | 7.1 (1/14) | 0 |
Biphasic | 94.2 (163/173) | 100 (8/8) | 90.0 (9/10) | 88.0 (22/25) | 95.5 (21/22) | 90.0 (9/10) | 100 (6/6) | 100 (15/15) | 93.9 (46/49) | 92.9 (13/14) | 100 (14/14) |
Preferred heart rate target with rate control: | |||||||||||
≤ 80 beats per minute | 72.5 (124/171) | 100 (8/8) | 40.0 (4/10) | 87.5 (21/24) | 95.5 (21/22) | 90.0 (9/10) | 66.7 (4/6) | 86.7 (13/15) | 55.1 (27/49) | 57.1 (8/14) | 69.2 (9/13) |
≤ 110 beats per minute‡ | 25.1 (43/171) | 0 | 60.0 (6/10) | 12.5 (3/24) | 4.5 (1/22) | 10.0 (1//10) | 33.3 (2/6) | 13.3 (2/15) | 36.7 (18/49) | 42.9 (6/14) | 30.8 (4/13) |
median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | median, IQR | |
n§ | n | n | n | n | n | n | n | n | n | n | |
No. ECVs/year | 100 (50–200) | 105 (90–200.5) | 30 (9–70) | 120 (85–200) | 300 (150–500) | 85 (15–200) | 225 (115–300) | 70 (40–120) | 50 (24–126.5) | 225 (80–280) | 111(100–168) |
n = 170 | n = 8 | n = 10 | n = 23 | n = 22 | n = 10 | n = 6 | n = 15 | n = 48 | n = 14 | n = 14 | |
No. PCVs/ year | 100 (37.5-200) | 102 (32.5-185) | 50 (20–80) | 150 (30–200) | 60 (25–100) | 175 (100–250) | 108 (50–200) | 150 (40–250) | 121 (98–300) | 15 (4–30) | 68 (30–140) |
n = 168 | n = 8 | n = 9 | n = 22 | n = 21 | n = 10 | n = 6 | n = 15 | n = 48 | n = 14 | n = 14 | |
Number of ablation procedures (among those performing ablations) | 156 (53–300) | 46 (35–179) | 64 (20–180) | 300 (112–450) | 300 (155–400) | 210 (120–480) | 440 (279–669) | 105 (53–171) | 125 (40–188) | 250 (120–856) | 35 (19–88) |
n = 112 | n = 6 | n = 10 | n = 19 | n = 18 | n = 6 | n = 4 | n = 12 | n = 29 | n = 3 | n = 5 | |